Onkologie. 2009:3(1):48-52

The possibility of laboratory testing for onkological patients. Part 2

Mirka Nekulová, Marta Šimíčková, Dalibor Valík
Masarykův onkologický ústav, Brno

The examinations of tumor markers and the other laboratory parameters in serum, plama or tissue of patients with malignant diagnoses,

their validity (sensitivity and specificity), biological half-time, timing and applications in terms of recommendations of international working

groups for tumor markers are summarized in the view of clinical oncology. Also individual characteristics for tumor markers and their

accurate indications are presented as well as perspective metods for future.

Keywords: tumor markers, biological half-time, timing, indications, validity.

Published: March 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nekulová M, Šimíčková M, Valík D. The possibility of laboratory testing for onkological patients. Part 2. Onkologie. 2009;3(1):48-52.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, Zilembo ND. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999 Sep 1; 86(5): 858-865. Go to original source...
    2. Beneduce L, Castaldi F, Marino M, Quarta S, Ruvoletto M, Benvegn? L, Calabrese F, Gatta A, Pontisso P, Fassina G. Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Cancer. 2005; 103: 2558-2565. Go to original source... Go to PubMed...
    3. Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem. 2004 Jul; 37(7): 529-540. Go to original source... Go to PubMed...
    4. Bensalah K, Lotan Y, Karam JA, Shariat SF. New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis. 2008; 11: 112-120. Go to original source... Go to PubMed...
    5. Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tum marker in patients with pancreatic cancer. Oncology, 2006; 70: 255-264. Go to original source... Go to PubMed...
    6. Brawer MK. Prostate specific antigen. Seminars in Surg. Oncol. 2000; 18: 3-9. Go to original source...
    7. Cole LA, Sutton JM. Selecting an appropriate hCG test for managing gestational trophoblastic disease and cancer. J Reprod Med. 2004; 49: 545-553. Go to PubMed...
    8. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007; 43: 1348-1360. Go to original source... Go to PubMed...
    9. Duffy MJ. Serum Tumor Markers in Breast Cancer: Are They of Clinical Value? Clinical Chemistry; 2006; 52: 3345-3351. Go to original source... Go to PubMed...
    10. Filella X, Alcover J, Molina R, Gíiménez N, Rodrígez Aů, Jo J, Carretero P, Ballesta A.M. Clinical usefulness of free PSA fraction as an indicator of prostate cancer. Int. J. Cancer 1995; 63: 780. Go to original source... Go to PubMed...
    11. Fonseca R, San Miguel J. Prognostic factors and staging in multiple myeloma. Hematol Oncol Clin North Am. 2007; 21: 1115-1140. Go to original source... Go to PubMed...
    12. Gadducci A, Tana R, Cosio S, Genazzani AR. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol. 2008; 66: 10-20. Go to original source... Go to PubMed...
    13. Giannelli G, Fransvea E, Trerotoli P, Beaugrand M, Marinosci F, Lupo L, Nkontchou G, Dentico P, Antonaci S. Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. Clin Chim Acta. 2007; 383: 147-152. Go to original source... Go to PubMed...
    14. Guadani F, Roselli M, Ferroni P, Spila A, Cavaliere F, Casaldi V, Wapner G, Abbolito MR, Greiner JW, et al. CA 72-4 serum marker - a new tool in the management of carcinoma patients. Cancer Invest. 1995; 13: 227-238. Go to original source... Go to PubMed...
    15. Harris L, Fritsche H, Mennel R, Norton L, Ravdin PS, Taube, Somerfield MR, Hayes DF, Bast Jr RC. American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. J Clin Oncol; 2007; 25: 5287-5312. Go to original source... Go to PubMed...
    16. Hung MCh, Lau YK. Basic science of HER2/neu: A review. Sem. In Oncol. 1999; 26: 51-59.
    17. Kato H. Recent progress in biology and clinical use of squamous cell carcinoma antigen.Tumor Marker Update 1996; 8: 177-179.
    18. Kaušitz J. Rádioimunoanalýza v onkologii, Veda, Bratislava, 1991.
    19. Komise NIH pro vytvoření konsenzu o karcinomu ovaria. JAMA-CS 1995; 3: 463.
    20. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr; ASCO. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006 Nov 20; 24(33): 5313-5327. Go to original source... Go to PubMed...
    21. Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett. 2007; 249: 30-39. Go to original source... Go to PubMed...
    22. Masopust J. Alfa-fetoprotein: Historie a význam jeho objevu I. Labor Aktuell 2007; 2: 8-11.
    23. Molina R, Filella X, Augé JM. ProGRP: a new biomarker for small cell lung cancer. Clin Biochem. 2004; 37: 505-511. Go to original source... Go to PubMed...
    24. Molina R, Barak V,van Dalen A, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Sölétormos G, Stieber P. Tumor Markers in Breast Cancer - European Group on Tumor Markers Recommendations. Tumor Biol; 2005; 26: 281-293. Go to original source... Go to PubMed...
    25. Munkarah A, Chatterjee M, Tainsky MA. Update on ovarian cancer screening. Curr. Opin. Obstet. Gynecol. 2007; 19: 22-26. Go to original source... Go to PubMed...
    26. Nekulová M, Šimíčková M, Pecen L. Software system BIANTA for assisting localization of primary tumor. Labor Aktuell, 1998; supplementum, 24-25.
    27. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, Schröder FH, Carter HB, Wolters T, van den Bergh RC, Gosselaar C, Bangma CH, Roobol MJ. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol. 2008; 53: 468-477. Go to PubMed...
    28. Stephan C, Jung K, Lein M, Diamandis EP. PSA and other tissue kallikreins for prostate cancer detection. Eur J Cancer. 2007; 43: 1918-1926. Go to original source... Go to PubMed...
    29. Tiseo M, Ardizzoni A, Cafferata MA, Loprevite M, Chiaramondia M, Filiberti R, Marroni P, Grossi F, Paganuzzi M. Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer. Anticancer Res. 2008; 28: 507-513.
    30. Tsimberidou AM, Kantarjian HM, Wen S, O'Brien SCortes J, Wierda WG, Koller C, Pierce S, Brandt M, Freireich EJ, Keating MJ, Estey EH. The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1, 180 patients. Clin Cancer Res. 2008 Feb 1; 14(3): 721-730. Go to original source... Go to PubMed...
    31. Tyrey L. Human chorinonic gonadotropin: Properties and assay methods. Seminars in Oncol., 1995; 22: 121-129.
    32. Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Skates S, Chan DW, Bast RC Jr. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol. 2007; 107: 526-531. Go to original source... Go to PubMed...
    33. Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M. Serum Proteomics and Biomarkers in Hepatocellular Carcinoma and Chronic Liver Disease. Clin Cancer Res. 2008; 14: 470-477. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.